Department of Intensive Care Medicine, Royal Brisbane and Womens Hospital, Herston, Brisbane, 4029, Queensland, Australia.
Curr Pharm Biotechnol. 2011 Dec;12(12):1991-5. doi: 10.2174/138920111798808248.
Intensive care medicine deals with the critically ill; these patients usually have multiple organ failure, and complex medical conditions. The mortality in Australia and New Zealand among this population is approximately 16.1%, with approximately 24.2% having existing co-morbidities, and 23.4% of these patients experiencing sepsis or septic shock. Sepsis is a clinical syndrome that traditionally was regarded as a physiological maladaptive response to a foreign pathogen and ranges in disease severity from simple sepsis to septic shock, a life threatening condition, associated with multiple organ failure. Sepsis has profound effects on all systems of the body, and most notably the cardiovascular, renal and hepatic systems. There has been much research into the septic critically ill patient and recent developments in basic pharmacology and physiology has yielded results applicable to clinical practice. Sepsis may induce a state of increased cardiac output, which has significant effects on drug pharmacokinetics and pharmacodynamics. This increased cardiac output increases both renal and hepatic blood flow, and alters rates of antibiotic metabolism, and excretion. There are also alterations in the fluid compartments of the septic critically ill, that results in an altered volume of distribution, and ultimately decreased antibiotic concentrations at their site of action. This article will examine and review in detail the septic critically ill patient, and the effects that sepsis has on physiology and the resulting altered antibiotic pharmacokinetics and pharmacodynamics. Current knowledge suggests that the medical prescriber should be weary of antibiotic dosing in the septic critically ill, and consider alternative dosing regimes that are individualized to the patient in order to maximize efficacy.
重症监护医学涉及危重病患者;这些患者通常有多器官衰竭和复杂的医疗状况。在澳大利亚和新西兰,该人群的死亡率约为 16.1%,约 24.2%存在合并症,23.4%的患者发生脓毒症或感染性休克。脓毒症是一种临床综合征,传统上被认为是对病原体的生理适应性反应失调,疾病严重程度从单纯脓毒症到感染性休克不等,感染性休克是一种危及生命的疾病,与多器官衰竭有关。脓毒症对身体的所有系统都有深远的影响,尤其是心血管、肾脏和肝脏系统。对脓毒症危重患者进行了大量研究,基础药理学和生理学的最新发展产生了适用于临床实践的结果。脓毒症可能引起心输出量增加,这对药物药代动力学和药效学有重大影响。这种心输出量的增加增加了肾脏和肝脏的血流量,并改变了抗生素代谢和排泄的速度。脓毒症危重患者的体液也会发生改变,导致分布容积改变,最终导致作用部位的抗生素浓度降低。本文将详细检查和审查脓毒症危重患者,以及脓毒症对生理学的影响,以及由此导致的抗生素药代动力学和药效学改变。目前的知识表明,对于脓毒症危重患者,医生应该警惕抗生素的剂量,并考虑针对患者个体化的替代剂量方案,以最大限度地提高疗效。